22235-25-2

Usage

Uses

Used in Organic Synthesis:
3-Amino-5-trifluoromethyl-benzoic acid methyl ester is used as an intermediate in organic syntheses for its unique reactive properties, which facilitate the creation of a range of chemical products.
Used in Pharmaceutical Industry:
3-Amino-5-trifluoromethyl-benzoic acid methyl ester is used as a building block in the development of pharmaceutical compounds, leveraging its structural features to contribute to the synthesis of new drugs.
Used in Chemical Research:
3-Amino-5-trifluoromethyl-benzoic acid methyl ester is used as a research tool in chemical studies, allowing scientists to explore its properties and potential applications in various fields.

InChI:InChI=1/C9H8F3NO2/c1-15-8(14)5-2-6(9(10,11)12)4-7(13)3-5/h2-4H,13H2,1H3

Upstream product

• 67-56-1 methanol 
• 328-68-7 3-amino-5-(trifluoromethyl)benzoic acid 
• 454-92-2 3-(trifluoromethyl)benzoic acid 
• 328-80-3 3-nitro-5-trifluoromethyl-benzoic acid 
• 22227-63-0 methyl 3-nitro-5-(trifluoromethyl)-benzoate 

Downstream Products

• 955947-12-3 3-isothiocyanato-5-trifluoromethyl-benzoic acid methyl ester 
• 334792-87-9 Methyl 3-(4-oxopiperidin-1-yl)-5-(trifluoromethyl)benzoate 
• 537039-44-4 [3-amino-5-(trifluoromethyl)phenyl]methanol 
• 334792-91-5 methyl 3-(4-aminopiperidin-1-yl)-5-(trifluoromethyl)benzoate 
• 334792-88-0 methyl 3-(4-hydroxypiperidin-1-yl)-5-(trifluoromethyl)benzoate 
• 334792-90-4 methyl 3-(4-azidopiperidin-1-yl)-5-(trifluoromethyl)benzoate 
• 334792-89-1 methyl 3-{4-(methanesulfonyloxy)-piperidin-1-yl}-5-(trifluoromethyl)benzoate 
• 334792-92-6 methyl 3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}-5-(trifluoromethyl)benzoate 
• 334792-93-7 3-(4-(pyrimidin-2-ylamino)piperidin-1-yl)-5-(trifluoromethyl)benzoic acid 
• 334792-95-9 (2S)-benzenesulfonylamino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}-5-(trifluoromethyl)benzoylamino]propionic acid 
• 334792-94-8 tert-butyl (2S)-benzenesulfonylamino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}-5-(trifluoromethyl)benzoylamino]propionate 
• 677704-77-7 3-ethylamino-5-(trifluoromethyl)-benzoic acid methyl ester 
• 1202635-15-1 C₁₇H₁₀F₆N₂O₃ 
• 1214361-12-2 methyl 3-chloro-5-(trifluoromethyl)benzoate 

Relevant academic research and scientific papers

UREA DERIVATIVE AND USE THEREFOR

The purpose of the present invention is to provide a compound with inhibitory activity on Discoidin Domain Receptor 1. The present invention provides a urea derivative represented by the formula (I) below or a pharmaceutically acceptable salt thereof.

UREA DERIVATIVE AND USE THEREFOR

The purpose of the present invention is to provide a compound with inhibitory activity on Discoidin Domain Receptor 1. The present invention provides a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof.

Enantioselective Synthesis of Quaternary Δ4- and Δ5-Dehydroprolines Based on a Two-Step Formal [3+2] Cycloaddition of α-Aryl and α-Alkyl Isocyano(thio)acetates with Vinyl Ketones

A divergent synthesis of optically active quaternary Δ4- and Δ5-dehydro prolines is developed based on the first catalytic enantioselective conjugate addition of α-substituted isocyano(thio)acetates to vinyl ketones that is general for both α-aryl and α-alkyl isocyano(thio)acetates. The new tetrasubstituted C?N stereocenter is formed without the need of any metal salt due to a bifunctional tertiary amine/squaramide catalyst, featuring a bulky polyaryl sidearm and an unusually short squaramide diamide H???H interatomic distance in the solid state.

Fluorescent non-peptidic RGD mimetics with high selectivity for αvβ3 vs αiIbβ3 integrin receptor: Novel probes for in vivo optical imaging

Integrins are heterodimeric transmembrane protein receptors consisting of different α and β subunits. αvβ3 integrins are overexpressed on many tumor cells and tumor-associated angiogenic vessels, whereas αIIbβ3 is a receptor for, e.g., fibrinogen and mediates platelet aggregation. In this study, a near-infrared fluorescent imaging probe has been designed and synthesized by conjugating fluorescent dyes to a non-peptidic, pharmacophore-based ligand, based on a molecular modeling design approach. Affinity values were determined, and in vitro cell binding assays and preliminary in vivo xenograft studies in nude mice were performed to evaluate target binding. Competition assays revealed excellent binding and selectivity to αvβ3 compared to that for αIIbβ3. In vitro, the probe showed high target binding on αvβ3-positive M-21 cells and negligible binding to αvβ3-negative MCF-7 cells. In vivo, the tracer is able to image target expression in U-87 xenografts with a maximum signal-to-noise ratio (SNR) of 2.5:1 at 24 h after injection.

PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS

JAK1 inhibitors of structural formula (I), wherein Ar1, Ar2, Q, W, X, Y, and Z are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES

The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.

AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS

The present invention provides a compound of formula (I), wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

NK-1 AND SEROTONIN TRANSPORTER INHIBITORS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part IV: Preliminary control of αvβ3 selectivity by meta-oriented substitution

To establish the in vivo efficacy of αvβ3/αIIbβ3 dual antagonists possessing a tricyclic pharmacophore, a corresponding αvβ3-selective antagonist was required as a control. We initially too